# PMV Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pmv-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Princeton, US
- Website: www.pmvpharma.com
- Total disclosed funding: $236M
- Latest round: Series D (Jul 17, 2020)
- Investors on record: 11

## About

PMV Pharmaceuticals, Inc. is focused on developing innovative therapies targeting the p53 protein, aiming to restore its tumor suppressor functions in cancer treatment, particularly for breast, lung, and colorectal cancers.Founded in 2013 and headquartered in the United States, PMV Pharmaceuticals, Inc. specializes in cancer therapies targeting the mutated p53 protein. The company successfully raised USD 211.7 mn in an IPO on September 24, 2020, indicating a significant advancement in their operational strategy. The company's founder has a history of involvement in biotechnology ventures, although specific details about previous companies are not available.PMV Pharma’s core focus revolves around the development of innovative therapies that target the p53 protein, a critical tumor suppressor that is often mutated in various cancers. The company employs a unique approach to restore the normal function of mutated p53 proteins by structurally correcting their geometry, thus reestablishing their tumor-suppressing capabilities. These therapies are aimed at treating various cancer types where p53 mutations play a significant role, including breast, lung, and colorectal cancers. PMV Pharma's product offerings are currently in various stages of clinical trials, indicating a commitment to advancing the science of p53 in oncology. The company’s services cater to oncology specialists, healthcare providers, and research institutions across North America and Europe, targeting a diverse client base that includes clinical researchers and pharmaceutical partners engaged in cancer treatment development.PMV Pharma generates revenue primarily through partnerships and collaborations with other pharmaceutical companies, facilitating the advancement of its proprietary therapies from clinical development into potential commercialization. The revenue structure involves milestone payments, royalties on future sales, and co-development agreements based on the successful progression of their clinical trials. As the company’s therapies advance through developmental phases, it may establish further agreements with healthcare organizations and research institutions to bolster its market presence. Specific financial details regarding pricing plans or transactional structures are not disclosed, but the emphasis remains on fostering strategic partnerships within the oncology sector to enhance therapeutic reach and efficacy.

## Funding rounds

- Series D, Jul 17, 2020, $70M — OrbiMed Advisors, Wellington Management, Viking Global Investors, Nextech, RA Capital Management, Avoro Capital Advisors, Boxer Capital
- Series C, Nov 12, 2019, $62M — InterWest Partners, OrbiMed Advisors, OUP (Osage University Partners), Topspin Partners, Viking Global Investors, Nextech, Boxer Capital, Euclidean Capital
- Series B, Feb 22, 2017, $74M — InterWest Partners, OrbiMed Advisors, OUP (Osage University Partners), Topspin Partners, Euclidean Capital
- Series A, Dec 2, 2014, $30M — InterWest Partners, OrbiMed Advisors, OUP (Osage University Partners)

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C, Series D
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B, Series C
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series B, Series C
- Euclidean Capital — Series B, Series C
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C, Series D
- Nextech (https://capitalatlas.ai/funds/nextech) — Series C, Series D
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C, Series D
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- Avoro Capital Advisors — Series D